SBC Medical Group Holdings Inc. (SBC)
Nasdaq · Services-Offices & Clinics Of Doctors Of Medicine · Services · CIK 1930313 · fiscal year ends in Dec
Closing price $5.68 on 29 Oct 2026; 52-week range $2.87 to $5.68.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $175.2M
- Revenue growth
- -6.9%
- Net income, last twelve months
- $49.0M
- Earnings per share
- $0.47
- Gross margin
- 71.9%
- Operating margin
- 37.3%
- Net margin
- 28.0%
- Free cash flow
- $61.8M
- Return on equity
- 18.6%
- Market value
- $582.6M
- Price to earnings
- 12.1x
- Cash
- $184.3M
- Debt
- $37.8M
- Debt to equity
- 0.14
- Shares outstanding
- 102.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $173.6M | $67.5M | $51.0M | $0.50 | $23.3M | 10-K filed 27 Mar 2026 |
| FY2024 | 31 Dec 2024 | $205.4M | $70.3M | $46.6M | $0.48 | $18.0M | 10-K filed 28 Mar 2025 |
| FY2023 | 31 Dec 2023 | $193.5M | $70.7M | $39.4M | $0.42 | $42.1M | 10-K filed 28 Mar 2025 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $49.2M | $10.7M | $0.10 |
| Q1 FY2026 | 31 Mar 2026 | $43.1M | $11.3M | $0.11 |
| Q4 FY2025 | 31 Dec 2025 | $39.6M | $14.2M | $0.14 |
| Q3 FY2025 | 30 Sep 2025 | $43.4M | $12.8M | $0.12 |
| Q2 FY2025 | 30 Jun 2025 | $43.4M | $2.5M | $0.02 |
| Q1 FY2025 | 31 Mar 2025 | $47.3M | $21.5M | $0.21 |
| Q4 FY2024 | 31 Dec 2024 | $44.4M | $6.5M | $0.05 |
| Q3 FY2024 | 30 Sep 2024 | $53.1M | $2.8M | $0.03 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Procurement Services | $56.1M | 32.3% |
| Franchising | $45.9M | 26.5% |
| Management Services | $29.6M | 17.1% |
| Rental Services | $23.0M | 13.3% |
| Other | $18.9M | 10.9% |
Company events
The newest 8-K filings of 46 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 13 Aug 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 14 Jul 2026 | 8-K | Delisting notice, Shareholder vote, Shareholder rights change, Bylaws or fiscal year change | 3.01, 3.03, 5.03, 5.07, 9.01 |
| 20 May 2026 | 8-K | Leadership change | 5.02 |
| 14 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 23 Apr 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 27 Mar 2026 | 8-K | Results, Investor update, Other events | 2.02, 7.01, 8.01, 9.01 |
| 5 Jan 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 31 Dec 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 15 Dec 2025 | 8-K | Other events | 8.01, 9.01 |
| 14 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 13 Nov 2025 | 8-K | Other events | 8.01, 9.01 |
| 13 Aug 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 142 held.
| Filed | Form | Period |
|---|---|---|
| 13 Aug 2026 | 10-Q | 30 Jun 2026 |
| 13 Aug 2026 | 8-K | 13 Aug 2026 |
| 14 Jul 2026 | 8-K | 8 Jul 2026 |
| 28 May 2026 | ARS | 31 Dec 2025 |
| 28 May 2026 | DEFA14A | – |
| 28 May 2026 | DEF 14A | 28 May 2026 |
| 20 May 2026 | 8-K | 14 May 2026 |
| 15 May 2026 | PRE 14A | 15 May 2026 |
| 14 May 2026 | 10-Q | 31 Mar 2026 |
| 14 May 2026 | 8-K | 14 May 2026 |
| 30 Apr 2026 | 10-K/A | 31 Dec 2025 |
| 23 Apr 2026 | 8-K | 19 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 28 Apr 2026 | Aikawa Yoshiyuki, Chairman and CEO | Sale outside a trading plan | 465,000 | $3.02 | $1.4M | 78,839,460 | 29 Apr 2026 |
| 21 Apr 2026 | Aikawa Yoshiyuki, Chairman and CEO | Sale outside a trading plan | 3,100,000 | $3.02 | $9.4M | 79,304,460 | 23 Apr 2026 |
| 6 Mar 2026 | Aikawa Yoshiyuki, Chairman and CEO | Sale outside a trading plan | 4,422,900 | $2.12 | $9.4M | 861,600 | 10 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 21 Apr 2026 | Yoshiyuki Aikawa | 13D amended | 82.2% | 84.3M |
| 13 Mar 2026 | Aikawa Equity Management Co., Ltd. | 13G | 5.2% | 5.3M |
| 10 Mar 2026 | Yoshiyuki Aikawa | 13D amended | 85.2% | 87.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 750.8K | -7.75% | 3.91 |
| 30 Sep 2026 | 813.9K | +13.43% | 3.37 |
| 15 Sep 2026 | 717.5K | +3.07% | 4.06 |
| 31 Aug 2026 | 696.2K | +3.21% | 3.43 |
| 14 Aug 2026 | 674.5K | -17.13% | 4.65 |
| 31 Jul 2026 | 814.0K | -11.02% | 12.13 |
| 15 Jul 2026 | 914.8K | +66.58% | 9.75 |
| 30 Jun 2026 | 549.2K | +45.45% | 2.69 |
Funds that hold it
From each fund's latest Form 13F.
60 funds held it at 30 Jun 2026: 45 added and 7 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Lumbard & Kellner, LLC | 1,727,208 | $5.3M | +1,709,935 |
| BlackRock, Inc. | 924,002 | $2.8M | +504,362 |
| Geode Capital Management, LLC | 427,864 | $1.3M | +132,085 |
| Citadel Advisors LLC | 144,718 | $445.7K | +144,718 |
| Vanguard Capital Management LLC | 135,783 | $418.2K | -456 |
| Northern Trust Corp. | 131,204 | $404.1K | +40,065 |
| Vanguard Portfolio Management LLC | 128,295 | $395.1K | +64,748 |
| Hillsdale Investment Management Inc. | 124,800 | $384.4K | +124,800 |
| Segall Bryant & Hamill, LLC | 81,307 | $250.4K | 0 |
| Vanguard Fiduciary Trust Co. | 66,281 | $204.1K | +3,808 |
Peers
Companies in the same industry.
- Hims & Hers Health, Inc. (HIMS): revenue $2.6B, market value $6.9B
- Teladoc Health, Inc. (TDOC): revenue $2.5B, market value $1.6B
- Starling Oncology, Inc. (STLN): revenue $587.2M, market value $666.6M